Donepezil, rivastigmine, galantamine and memantine for ...

placebo-controlled study of donepezil in patients
with mild to moderate AD. Neurology 2001;
57:489–95.
48. Nunez M, Hasselbalch S, Heun R, Kalisvaart CJ,
Kozubski W, Sakka P, et al. Donepezil-treated
Alzheimer’s disease patients with apparent initial
cognitive decline demonstrate significant benefits
when therapy is continued: results from a
randomised, placebo-controlled trial. Poster
presented at the Second Annual Dementia
Congress, 12–14 September 2003, Washington,
DC, 2003.
49. Holmes C, Wilkinson D, Dean C, Vethanayagam S,
Olivieri S, Langley A, et al. The efficacy of
donepezil in the treatment of neuropsychiatric
symptoms in Alzheimer’s disease. Neurology 2004;
63:214–19.
50. Burns A, Rossor M, Hecker J, Gauthier S, Petit H,
Moller HJ, et al. The effects of donepezil in
Alzheimer’s disease – results from a multinational
trial. Dement Geriatr Cogn Disord 1999;10:237–44.
51. Rogers SL, Farlow MR, Doody RS, Mohs R,
Friedhoff LT. A 24-week, double-blind, placebocontrolled
trial of donepezil in patients with
Alzheimer’s disease. Donepezil Study Group.
Neurology 1998;50:136–45.
52. Rogers SL, Doody RS, Mohs RC, Friedhoff LT,
Alter M, Apter J, et al. Donepezil improves
cognition and global function in Alzheimer disease:
a 15-week, double-blind, placebo-controlled study.
Arch Intern Med 1998;158:1021–31.
53. Rogers SL, Friedhoff LT, Apter JT, Richter RW,
Hartford JT, Walshe TM, et al. The efficacy and
safety of donepezil in patients with Alzheimer’s
disease: results of a US multicentre, randomized,
double-blind, placebo-controlled trial. Dementia
1996;7:293–303.
54. Greenberg SM, Tennis MK, Brown LB, Gomez-
Isla T, Hayden DL, Schoenfeld DA, et al.
Donepezil therapy in clinical practice: a
randomized crossover study. Arch Neurol 2000;
57(9):1380.
55. Seltzer B, et al. [Commercial confidential
information removed] A 24-week, multicenter,
randomized, double-blind, placebo-controlled
evaluation of the efficacy and safety of donepezil
hydrochloride (E2020) in patients with early
Alzheimer’s disease. Industry submission, 2004.
56. Wimo A, Winblad B, Engedal K, Soininen H,
Verhey F, Waldemar G, et al. An economic
evaluation of donepezil in mild to moderate
Alzheimer’s disease: results of a 1-year, doubleblind,
randomized trial [published erratum
appears in Dement Geriatr Cogn Disord.
2003;16:102]. Dement Geriatr Cogn Disord 2003;
15:44–54.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 1
57. Corey-Bloom J, Anand R, Veach J. A randomized
trial evaluating the efficacy and safety of ENA 713
(rivastigmine tartrate), a new acetylcholinesterase
inhibitor, in patients with mild to moderately
severe Alzheimer’s disease. Int J Geriatr
Psychopharmacol 1998;1:55–65.
58. Rösler M, Anand R, Cicin SA, Gauthier S, Agid Y,
Dal Bianco P, et al. Efficacy and safety of
rivastigmine in patients with Alzheimer’s disease:
international randomised controlled trial. BMJ
1999;318:633–40.
59. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy
and tolerability of rivastigmine in patients with
dementia of the Alzheimer type. Curr Ther Res Clin
Exp 1998;59:837–45.
60. Forette F, Anand R, Gharabawi G. A phase II study
in patients with Alzheimer’s disease to assess the
preliminary efficacy and maximum tolerated dose
of rivastigmine. Eur J Neurol 1999;6:423–9.
61. Raskind MA, Peskind ER, Wessel T, Yuan W.
Galantamine in AD. A 6-month randomised,
placebo-controlled trial with a 6-month extension.
Neurology 2000;54:2261–8.
62. Rockwood K, Mintzer J, Truyen L, Wessel T,
Wilkinson D. Effects of a flexible galantamine dose
in Alzheimer’s disease: a randomised, controlled
trial. J Neurol Neurosurg Psychiatry 2001;71:589–95.
63. Tariot P, Solomon PR, Morris J, Kershaw P,
Lilienfeld S, Ding C. A 5-month, randomised,
placebo-controlled trial of galantamine in AD.
Neurology 2000;54:2269–76.
64. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and
safety of galantamine in patients with mild to
moderate Alzheimer’s disease: Multicentre
randomised controlled trial. BMJ 2000;321:1445–9.
65. Wilkinson D, Murray J. Galantamine: a
randomized, double-blind, dose comparison in
patients with Alzheimer’s disease. Int J Geriatr
Psychiatry 2001;16:852–7.
66. Wilkinson D, Lilienfeld S, Truyen L. Galantamine
improves activities of daily living in patients with
alzheimer’s disease: a 3 month placebo-controlled
study. In Proceedings of the Sixth International
Stockholm/Springfield Symposium on Advances in
Alzheimer Therapy, Stockholm, 5–8 April 2000.
p. 233.
67. Cummings JL, Schneider L, Tariot PN,
Kershaw PR, Yuan W. Reduction of behavioral
disturbances and caregiver distress by galantamine
in patients with Alzheimer’s disease. Am J Psychiatry
2004;161:532–8.
68. Fuschillo C, La Pia S, Campana F, Pinto A,
De Simone L. Cognitive deficits in Alzheimer’s
disease: Treatment with acetylcholinesterase
inhibitor agents. Arch Gerontol Geriatr 2001;7:
151–8.
155